Phase I Clinical Trial of Intravenous L-ascorbic Acid Following Salvage Chemotherapy for Relapsed B-cell non-Hodgkin's Lymphoma

To determine the safety and the appropriate dose of intravenous l-ascorbic acid (AA) in conjunction with chemotherapy for patients with relapsed lymphoma. Patients with relapsed CD20-positive B-cell non-Hodgkin's lymphoma, who were going to receive the CHASER regimen as salvage therapy, were en...

Full description

Saved in:
Bibliographic Details
Published inThe Tokai journal of experimental and clinical medicine Vol. 39; no. 3; p. 111
Main Authors Kawada, Hiroshi, Sawanobori, Masakazu, Tsuma-Kaneko, Mitsuyo, Wasada, Izumi, Miyamoto, Mitsuki, Murayama, Hiromichi, Toyosaki, Masako, Onizuka, Makoto, Tsuboi, Kosuke, Tazume, Kei, Shirasugi, Yukari, Ohmachi, Ken, Ogawa, Yoshiaki, Kobayashi, Hiroyuki, Ando, Kiyoshi
Format Journal Article
LanguageEnglish
Published Japan 20.09.2014
Subjects
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Ascorbic Acid - administration & dosage
Cyclophosphamide - administration & dosage
Cytarabine - administration & dosage
Dexamethasone - administration & dosage
Etoposide - administration & dosage
Female
Humans
Infusions, Intravenous
Lymphoma, B-Cell - drug therapy
Male
Middle Aged
Rituximab - administration & dosage
Salvage Therapy
Treatment Outcome
Online AccessGet more information

Cover

More Information
Summary:To determine the safety and the appropriate dose of intravenous l-ascorbic acid (AA) in conjunction with chemotherapy for patients with relapsed lymphoma. Patients with relapsed CD20-positive B-cell non-Hodgkin's lymphoma, who were going to receive the CHASER regimen as salvage therapy, were enrolled and treated with escalating doses of AA administered by drip infusion after the 2nd course of the CHASER regimen. The target plasma concentration immediately after AA administration was >15 mM (264 mg/dl). A serum AA concentration of >15 mM was achieved in 3 sequentially registered patients, all of whom had received a 75 g whole body dose. No obvious adverse drug reaction was observed in the patients. The trial was therefore successfully completed. Intravenous AA at a whole body dose of 75 g appears to be safe and sufficient to achieve an effective serum concentration. A phase II trial to evaluate the efficacy of intravenous AA in relapsed/refractory lymphoma patients will now be initiated.
ISSN:2185-2243